or Try an Advanced Search...

    Technical Analysis for OCGN - Ocugen, Inc.

    Grade Last Price % Change Price Change
    B 1.28 8.47% 0.10
    OCGN closed up 8.47 percent on Friday, April 26, 2024, on 48 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 3
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical OCGN trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 8.47%
    Oversold Stochastic Weakness 8.47%
    Fell Below 50 DMA Bearish 8.47%
    MACD Bearish Centerline Cross Bearish 8.47%
    Lower Bollinger Band Walk Weakness 8.47%
    Wide Bands Range Expansion 8.47%
    Oversold Stochastic Weakness 8.47%
    Older End-of-Day Signals for OCGN ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 12 hours ago
    60 Minute Opening Range Breakout about 13 hours ago
    Rose Above Previous Day's High about 13 hours ago
    Rose Above 50 DMA about 13 hours ago
    Up 5% about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OCGN Chart by TradingView
    Basic chart:

    Profile

    Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa

    Is OCGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 26 Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
    Apr 26 UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    Apr 26 Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    Apr 19 Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
    Apr 19 Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
    Apr 18 Ocugen stock jumps after $175M securities filing
    Apr 12 Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
    Apr 10 Ocugen says EU backs a U.S. trial for gene therapy
    Apr 10 Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
    Apr 8 Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
    See more OCGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.105
    52 Week Low 0.345
    Average Volume 11,184,731
    200-Day Moving Average 0.67
    50-Day Moving Average 1.27
    20-Day Moving Average 1.50
    10-Day Moving Average 1.34
    Average True Range 0.18
    RSI (14) 45.36
    ADX 25.18
    +DI 20.10
    -DI 23.10
    Chandelier Exit (Long, 3 ATRs) 1.55
    Chandelier Exit (Short, 3 ATRs) 1.64
    Upper Bollinger Bands 1.93
    Lower Bollinger Band 1.06
    Percent B (%b) 0.25
    BandWidth 58.26
    MACD Line -0.03
    MACD Signal Line 0.04
    MACD Histogram -0.0683
    Fundamentals Value
    Market Cap 328.32 Million
    Num Shares 257 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -4.00
    Price-to-Sales 25069.32
    Price-to-Book 2.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.46
    Resistance 3 (R3) 1.45 1.38 1.43
    Resistance 2 (R2) 1.38 1.33 1.39 1.42
    Resistance 1 (R1) 1.33 1.31 1.36 1.34 1.41
    Pivot Point 1.26 1.26 1.27 1.27 1.26
    Support 1 (S1) 1.21 1.21 1.24 1.22 1.15
    Support 2 (S2) 1.14 1.19 1.15 1.14
    Support 3 (S3) 1.09 1.14 1.13
    Support 4 (S4) 1.10